12 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 15 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 12, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Prevention: new trials by email Literature Review of Prevention trials Research Report on Prevention
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients Aprepitant 40mg, Placebo - Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 260 | 2026-02-27 | 2026-08-27 |
| Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin Sodium enoxaparin, Dimolegin, Dimolegin placebo - Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | Phase 3 | Completed | Avexima Diol LLC | 215 | 2024-07-22 | 2026-01-16 |
| Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. Cabotegravir Tablets, for oral use., Cabotegravir Extended-Release Injectable Suspension, for intramuscular use., Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use - Prevention | Phase 3 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 322 | 2024-04-01 | 2024-02-23 |
| A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried, Chirorab - Rabies, Prevention | Phase 3 | Unknown | Yisheng Biopharma (Singapore) Pte. Ltd. | 4500 | 2023-09-22 | 2024-07-23 |
| Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) Rivaroxaban 2.5 Mg Oral Tablet, Rivaroxaban placebo tablets - Stroke, Prevention | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 42 | 2020-08-22 | 2023-10-19 |
| Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia Aztreonam lysine, Aerogen Solo, CombiHaler - Ventilator Associated Pneumonia, Prevention | Phase 2 / Phase 3 | Terminated | Hospital Universitari Joan XXIII de Tarragona. | 9 | 2019-03-19 | 2021-07-01 |
| Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients Levofloxacin, Placebo Oral Tablet - Prevention | Phase 3 | Completed | Sheba Medical Center | 67 | 2017-08-01 | 2023-11-27 |
| Familias Unidas: Preventing Substance Abuse in Hispanic Youth Familias Unidas - Prevention, Family Function | Phase 2 / Phase 3 | Completed | University of Miami | 746 | 2010-08-01 | 2015-06-03 |
| Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin Esomeprazole, Placebo - Prevention | Phase 3 | Completed | AstraZeneca | 427 | 2010-02-01 | 2012-11-22 |
| A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty edoxaban, enoxaparin sodium - Prevention, Venous Thromboembolism | Phase 3 | Completed | Daiichi Sankyo Co., Ltd. | 610 | 2009-05-01 | 2019-03-05 |
| Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement Rivaroxaban (BAY59-7939), Enoxaparin - Prevention, Venous Thromboembolism | Phase 3 | Completed | Bayer | 2457 | 2006-02-01 | 2015-01-27 |
| Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. Rivaroxaban (BAY59-7939), Enoxaparin - Prevention, Venous Thromboembolism | Phase 3 | Completed | Bayer | 2531 | 2006-02-01 | 2014-10-27 |
| A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo - Healthy Adult Female Participants, Prevention | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3819 | 2004-06-16 | 2017-04-21 |
| Parent Education for Young Teen Females parent education - Prevention | Phase 2 / Phase 3 | Completed | Education Development Center, Inc. | 500 | 2003-09-01 | 2012-07-03 |
| Celecoxib as a Chemopreventive Agent in Current and Former Smokers Celecoxib, Placebo - Smoking, Prevention | Phase 3 | Completed | M.D. Anderson Cancer Center | 219 | 2001-11-01 | 2012-08-01 |
Venous Thromboembolism (4) · Smoking (2) · Duodenal Ulcer (1) · Embolism (1) · Papillomavirus Infections (1) · Pneumonia, Ventilator-Associated (1) · Postoperative Nausea and Vomiting (1) · Rabies (1) · Sexual Behavior (1) · Stomach Ulcer (1) · Stroke (1) · Substance-Related Disorders (1) · Thromboembolism (1) · Thrombosis (1) · Venous Thrombosis (1)
Cardiovascular Diseases (5) · Vascular Diseases (5) · Embolism and Thrombosis (4) · Infections (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Thromboembolism (3) · Behavior (2) · Disease Attributes (2) · Virus Diseases (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Chemically-Induced Disorders (1) · Communicable Diseases (1)
Enoxaparin (3) · Rivaroxaban (3) · enoxaparin sodium (2) · (+-)-(1'R*,2'S*,6'R*)-(2-hydroxy-4,6-dimethoxyphenyl)(3'-methyl-2'-(3''-methylbut-2''-enyl)-6-phenylcyclohex-3'-enyl)methanone (1) · Aprepitant (1) · Celecoxib (1) · Emtricitabine (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Esomeprazole (1) · Freeze Drying (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Levofloxacin (1) · Ofloxacin (1) · Tenofovir (1) · cabotegravir (1)
Bayer (2) · ANRS, Emerging Infectious Diseases (1) · AstraZeneca (1) · Avexima Diol LLC (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Daiichi Sankyo Co., Ltd. (1) · Education Development Center, Inc. (1) · Hospital Universitari Joan XXIII de Tarragona. (1) · M.D. Anderson Cancer Center (1) · Mazandaran University of Medical Sciences (1) · Merck Sharp & Dohme LLC (1) · Sheba Medical Center (1) · University of Miami (1) · Yisheng Biopharma (Singapore) Pte. Ltd. (1)
United States (4) · Canada (3) · China (2) · Colombia (2) · Denmark (2) · France (2) · Israel (2) · Italy (2) · Japan (2) · Mexico (2) · Norway (2) · Peru (2) · South Africa (2) · South Korea (2) · Spain (2)
Athena Sharifi-Razvi (1) · Drorit G Merkel, MD (1) · Guillermo Prado, PhD (1) · Jean-Michel Molina, Professor (1) · Jonathan M. Kurie, MD (1) · Kentaro Sugano, MD, PhD (1) · Maxim Roy, MD, FRCPC (1) · Monireh Ghazaeian (1) · Takeshi Fuji (1)
PMID 18579812, PMID 18582928, PMID 19493565, PMID 19652630, PMID 19935017, PMID 21629249, PMID 22518014, PMID 24326741, PMID 24391768, PMID 25050644, PMID 26472037, PMID 27080532, PMID 27980462, PMID 28207330, PMID 29041861, PMID 29074187, PMID 30514652, PMID 32184277, PMID 40037214, PMID 8888088
2005 (1), R01AA014515 (1)